← Eichor
Study identifier: NCT04960839 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Prophylactic Irradiation to the Contralateral Breast for BCAs Patients

Condition: Breast Cancer  ·  Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

PhaseNA
Planned participants323
Who can joinFemale, 30 Years to 70 Years
Healthy volunteersNo

About this study

Breast cancer is the most common cancer in women worldwide, with high mortality. About 5% to 10% of breast cancers are hereditary. Most inherited cases of breast cancer are associated with germline mutations in genes, such as BRCA1, BRCA2 and PALB2. The cumulative breast cancer risk for BRCA1, BRCA2 or PALB2 mutation carriers was high. Besides the increased breast cancer risk for the inherited mutation carriers, the risk of subsequent contralateral breast cancer for the mutation carriers with breast cancer was also significantly increased. Contralateral prophylactic mastectomy was usually recommended to the breast cancer patients with BRCA mutation. However, many breast cancer patients refused the contralateral prophylactic mastectomy, due to the surgical injury, potential surgical complications, deleteriously affected body image and sexuality. Solid evidence validated that radiotherapy after surgery resulted in a reduced local recurrence for three times lower than surgery alone. It is thought that radiation would eliminate the microscopic tumors which may already exist in the breast. Thus, we proposed that for the breast cancer patients with BRCA1, BRCA2 or PALB2 deleterious germline mutations, prophylactic irradiation to the contralateral breast may reduce the risk of subsequent contralateral breast cancer. And we would like to further compare the effect of prophylactic irradiation to the published data from traditional prophylactic contralateral mastectomy.

This description comes directly from the study's public registry record.

Talk to the study team

Yiding Chen, M.D.  ·  +86-571-87784527  ·  ydchen@zju.edu.cn

Jiaojiao Zhou  ·  +86-571-87214404  ·  zhoujj@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (8)

Department of Breast Surgery, Jiangxi Provincial Cancer HospitalJiangxi, Jiangxi, ChinaNot Yet Recruiting
Department of Breast Surgery, Obestrics and Gynecology Hospital of Fudan UniversityShanghai, Shanghai Municipality, ChinaNot Yet Recruiting
Department of Breast Surgery, Cancer Hospital of University of Chinese Academy of SciencesHangzhou, Zhejiang, ChinaNot Yet Recruiting
Department of Breast Surgery, the First Affiliated Hospital, College of Medicine, Zhejiang UniversityHangzhou, Zhejiang, ChinaNot Yet Recruiting
Department of Breast Surgery, the Second Affiliated Hospital, Zhejiang University School of MedicineHangzhou, Zhejiang, ChinaRecruiting
Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang UniversityHangzhou, Zhejiang, ChinaNot Yet Recruiting
Department of Oncology, Zhejiang HospitalHangzhou, Zhejiang, ChinaNot Yet Recruiting
Department of Breast Surgery, Yong Loo Lin School of Medicine, National University of SingaporeSingapore, SingaporeNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04960839